Incyte (INCY) Price Target Lifted on CALR Antibody Program Optimism

Group 1 - Incyte Corporation (NASDAQ:INCY) is recognized as one of the top biotech stocks to consider for investment, with RBC Capital maintaining a Sector Perform rating and raising its price target from $72 to $81 [1] - The increase in price target is attributed to the growing interest in Incyte's '989 CALR antibody program, especially in anticipation of updates from the American Society of Hematology (ASH) [1][2] - RBC Capital expects key opinion leaders to seek at least a 30% reduction in spleen volume for myelofibrosis combination therapy and will monitor sustained responses and deeper variant allele frequency (VAF) for essential thrombocythemia treatment [2] Group 2 - Incyte Corporation is a leading global pharmaceutical company focused on developing treatments for various diseases, including cancer [2]